




03-19-01 Box SEQ/AN

PTO/SB/13/PCT (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

POCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION		PRIOR APPLICATION EXAMINER	ART UNIT
MWH-0303US2	CLASS	SUBCLASS		
	435; 536	6, 91.2; 23.5, 24.33	Joseph F. Murphy	

11046 U.S. PTO
09/811285



Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior international application Number PCT /US00/10125, filed on 13 APR 00 entitled Association of the Beta2-Adrenergic Receptor Haplotypes with Drug Response

which designated the United States.

Note: 37 CFR 1.53(c) or (d) cannot be used to file a continuation or divisional application of an international application which has not entered the national stage.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	21 - 20 =	1	x \$ 18.00 =	\$ 18.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	8 - 3 =	5	x \$ 80.00 =	400.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ =	
				BASIC FEE (37 CFR 1.16(a))	+ 710.00
				Total of above Calculations =	1,128.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				0.00
				TOTAL =	1,128.00

- Enclosed are the specification, claims and drawing(s).
- ☐ A statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 50-1293. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ is enclosed.
- ☒ Amend the specification by inserting before the first line the sentence: "This application is a ☒ continuation ☐ division of international application number PCT /US00/10125, filed 13 April 2000, (status, abandoned, pending etc.)."

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION, PAGE 2)

6. ☒ A declaration under 37 CFR 1.63 is enclosed.

7. ☐ Priority of foreign application number _____, filed on _____ in _____
is claimed under 35 U.S.C. 119(a) - (d).

☐ The certified copy is enclosed.

8. ☒ A preliminary amendment is enclosed.

9. ☒ Also enclosed: Computer Readable form of sequence listing with accompanying statement under 37
CFR 1.821(f)

Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

Melodie W. Henderson, Reg. No. 37, 848
Genaissance Pharmaceuticals, Inc.

5 Science Park
New Haven, CT 06511

March 16, 2001
Date

Melodie W. Henderson
Signature

Melodie W. Henderson
Typed or printed name

- ☐ Inventor(s)
☐ Assignee of complete interest. Certification under 37 CFR 3.73(b) is enclosed.
☒ Attorney or agent of record
☐ Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a) _____.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.;
Nandabalan, Krishnan; and Stephens, J. Claiborne.

Title: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES
WITH DRUG RESPONSE


Filed on: March 16, 2001

STATEMENT ACCOMPANYING SEQUENCE LISTING

(37 CFR 1.821(f) and MPEP 2422.06)

The undersigned hereby states that the information recorded in computer readable form is
identical to the written Sequence Listing submitted herewith.

Respectfully Submitted,



Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Reg. No. 37,848
Tel. No. 203-786-3421